寿命延长增加了癌症幸存者长期化疗并发症的可能性，其中一个繁琐的并发症为化疗诱发的周围神经病变（CIPN）。我们评估了底特律癌症幸存者（ROCS）队列中CIPN结果的比率。样本包括接受乳腺、结直肠、肺或前列腺癌化疗的1,034名非洲裔美国（AA）幸存者。CIPN患病率基于化疗后自我报告疼痛、麻木或刺痛恶化的首次发生。目前CIPN包括在调查时仍存在的症状，而持续CIPN症状持续存在于化疗后12个或更多月。CIPN严重程度被评为轻度、中度或严重。利用Logistic回归评估与不同类别CIPN相关的社会人口和临床因素。CIPN患病率为68%，其中53%为目前患病，52%为持续患病。基于患有CIPN的现有症状，症状严重程度分布包括32.2%为轻度，30.8%为中度，36.9%为严重。与患有CIPN（比值比、95%置信区间）有关的因素包括原发癌部位（乳腺：3.88、2.02-7.46）；（结直肠：5.37、2.69-10.73），诊断年龄较老的风险较低（0.66、0.53-0.83）以及离婚/分居婚姻状态（2.13、1.42-3.21）。目前的CIPN还与疾病进展更为显著的趋势（1.34、1.08-1.66）和更多合并症医学状况的趋势（1.23、1.09-1.40）有关，持续的CIPN也是如此。患有CIPN的严重程度与关节炎病史有关（1.55、1.06-2.26），而持续CIPN的严重程度与较高的BMI有关（1.58、1.07-2.35）。CIPN是AA癌症幸存者常见且持续的并发症。需要进一步的研究以改善我们对所有癌症幸存者中CIPN预测因素的理解。©2023 Springer Nature Switzerland AG以作者独家许可。

Improved life expectancy has increased the likelihood for long-term complications from chemotherapy among cancer survivors. One burdensome complication is chemotherapy-induced peripheral neuropathy (CIPN). We evaluated rates of CIPN outcomes in the Detroit Research on Cancer Survivorship (ROCS) cohort.The population included 1,034 African American (AA) survivors who received chemotherapy for breast, colorectal, lung or prostate cancer. CIPN prevalence was based on initial occurrence of worsening of self-reported pain, numbness or tingling after chemotherapy. Current CIPN included symptoms still present at the time of the survey, and persistent CIPN symptoms were present 12 or more months post-chemotherapy. CIPN severity was ranked as mild, moderate or severe. Logistic regression was utilized to evaluate sociodemographic and clinical factors associated with the various categories of CIPN.CIPN prevalence was 68%, with 53% current and 52% persistent. The symptom severity distribution based on prevalent CIPN included 32.2% mild, 30.8% moderate, and 36.9% severe. Factors associated with prevalent CIPN (odds ratio, 95% confidence interval) included primary cancer site (breast: 3.88, 2.02-7.46); and (colorectal: 5.37, 2.69-10.73), lower risk for older age at diagnosis (0.66, 0.53-0.83) and divorced/separated marital status (2.13, 1.42-3.21). Current CIPN was in addition, associated with more advanced stage disease trend (1.34, 1.08-1.66) and greater number of co-morbid medical conditions trend (1.23, 1.09-1.40), as was persistent CIPN. Severity of prevalent CIPN was associated with history of arthritis (1.55, 1.06-2.26) and severity of persistent CIPN with higher BMI (1.58, 1.07-2.35).CIPN is a common and persistent complication in AA cancer survivors. Further research is needed to improve our understanding of CIPN predictors in all groups of cancer survivors.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.